Therapeutic Area

Corticosteroid

Therapeutic area intelligence for Corticosteroid with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 6
Catalysts: 0
Companies: 4

Companies

Hikma →

Hikma Pharmaceuticals →

Sandoz →

Upsher Smith Labs →

Assets

Recent signals(6)

RegulatoryJune 19, 2026

FDA Grants AP Status for Methylprednisolone ANDA210985 by Ingenus Pharms

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for methylprednisolone submitted by Ingenus Pharms.

CompetitiveJune 19, 2026

Hikma's Methylprednisolone Sodium Succinate ANDA202691 Receives AP Status

Hikma's application for Methylprednisolone Sodium Succinate (ANDA202691) has received an Abbreviated Approval (AP) status from the FDA.

RegulatoryJune 18, 2026

Hikma's Methylprednisolone Sodium Succinate ANDA203125 Receives AP Status

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status of 'AP' for Hikma's Methylprednisolone Sodium Succinate.

RegulatoryJune 8, 2026

FDA Approves Supplement for Methylprednisolone Acetate by Sandoz

The FDA has approved a supplemental application for Methylprednisolone Acetate submitted by Sandoz.

RegulatoryJune 8, 2026

Sandoz's Methylprednisolone ANDA040194 Receives AP Status from FDA

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status to Sandoz for methylprednisolone.

RegulatoryJune 6, 2026

FDA Approves Deflazacort Supplement Application by Upsher Smith Labs

The FDA has approved a supplemental application for Deflazacort submitted by Upsher Smith Labs.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.